Articles On Adalta (ASX:1AD)

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

AdAlta boosts leadership of subsidiaries with appointments of two consultant chief medical officers AdCella’s Kevin Lynch will support selection of in-licensed cellular immunotherapies and the design and execution of Phase 1 clinical trial...

ASX edges slightly up by 0.12pc as traders rethink rate cuts Consumer staples shine while gold miners gain amid global tensions 29Metals plunges after cash reserve drop and production decline   The ASX ticked up higher by 0.1% on Wednesd...

Tony Locantro has been a client advisor/investment manager in the stockbroking industry since 1998. He’s focused on the small cap and emerging companies with a strong interest in identifying those in the mining, biotech and industrial secto...

Stockhead’s Sarah Hughan sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get the short end of the long story on the company’s latest news. The company’s formed a clinical advisory board to support the development of...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on AdAlta (ASX:1AD) recruiting a team of world leaders in idiopathic pulmonary fibrosis to form a company cli...

AdAlta forms a clinical advisory board to advance its lead i-body enabled drug candidate AD-214 Board members are renowned experts in pulmonary medicine and fibrosis AdAlta has also engaged a specialist adviser for Idiopathic Pulmonary Fib...

  ASX 200 index falls despite gains in energy stocks Smaller oil and gas firms benefit from rising crude prices Iron ore stocks drop as prices retreat   The ASX 200 index fell hard on Friday, down by 0.75%, despite some gains in the Ener...

  To register for today's webinar click here. Platina Resources Limited (ASX:PGM) has confirmed two gold intersections at its Challa Gold Project in Western Australia, including 12m at 0.66g/t Au from aircore hole CHAC0155. The findings sug...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Coles Group Ltd (ASX: COL) shares have enjoyed a strong run in 2024. They are up 18.7% this year to date and finished trading on Tuesday at $19.12 apiece. With the S&P/ASX 200 Index (ASX: XJO) 7.2% higher in the same period, Coles sh...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

The ASX ended higher after a slow start Energy stocks leading while telcos and miners lagged Asian stocks mostly declined amid ongoing economic weakness    After a sluggish start, the ASX ended Monday higher by 0.22% as September trading...

Local markets opened lower this morning, with the decline slightly exceeding expectations. Despite a decent performance on Wall Street overnight, which might have suggested a more positive start for the ASX, the Australian share market face...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode Tim chats with Tim Oldham, CEO and managing director at AdAlta (ASX:1AD). The biotech company is devo...

  Tim Oldham – CEO & Managing Director – AdAlta Limited (ASX:1AD) is a clinical-stage biotechnology company. The company’s lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis.

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX rises on Monday after Wall Street banked a belter on Friday All 11 local sectors higher, InfoTech winning the race for Best in Show Aruma Resources led the small caps winners   The local benchmark moved strongly into positive terri...

AdAlta entered collaboration with SYNthesis BioVentures Fund to establish AdCella during Q4 FY24 Cell Therapies chosen as preferred manufacturing partner for AdCella’s cellular immunotherapies Institutional investment, reduced expenditure...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

ASX starts June positively, extending May gains  Property prices in Australia rose by 0.8% in May, with Sydney remaining the most expensive city Lovisa plunges by -10% as John Cheston takes over as CEO   The ASX has started the month of...

1AD raises $1.9 million of new equity from the exercise of listed 1ADOA options, led by an existing major shareholder Options exercised at a 20% premium to the closing price on May 29 2024 Proceeds from exercised options to help AdAlta adv...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Stockhead’s Sarah Hughan sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get the short end of the long story on the company’s latest news. The Aussie biotech has chosen Cell Therapies as its preferred manufacturer fo...

AdAlta (ASX:1AD)  has announced an agreement under which Cell Therapies will be established as the preferred manufacturing partner of its cellular immunotherapies.

ASX flat on Monday,  ahead of Federal Budget Tuesday night Oil weakness drags Energy sector lower Chinese shares slump on new US tariffs   After advancing 1.5% last week, the ASX200 fell flat on Monday – greenish by 0.01% – dragged down m...

Optiscan signs deal with world-renowned Mayo Clinic AdAlta designates Cell Therapies as its manufacturing partner Ecofibre jumps after entering sell and leaseback agreement in US   Optiscan signs deal with Mayo Clinic Optiscan Imaging (AS...

  ASX to open higher as the S&P 500 inches toward a new high Tesla to spend US$500m in in expanding its charging network Treasurer Jim Chalmers calls critical minerals a “golden opportunity”   Aussie shares are poised to open lower o...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

The ASX belts one out on Monday, up 0.8pc All 11 sectors are better for it Canterbury Resources grows by half   The benchmark Aussie index has started the week with decisive and broad based gains. All 11 sectors ended Monday higher. US Fu...

AdAlta has received an institutional investment of up to $3m from New Life Sciences LLC and $700,000 from Meurs Group The two investments will allow the company to accelerate the recent SYNBV MoU An extended final repayment has also been s...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Stockhead’s Ashtyn Hiron sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get the short end of the long story on the company’s latest news. AdAlta announced a partnership with venture capital firm  SYNthesis BioVentur...

Special Report: AdAlta and SYNthesis BioVentures Fund (SYNBV) are collaborating to form AdCella, a jointly owned entity aimed at facilitating the entry of innovative cellular immunotherapies from Asia into western regulated markets, leverag...

It’s been a tough couple of years for ASX health care with challenging economic conditions including steep interest rates rises to combat soaring inflation hitting the sector like a nasty dose of influenza. Furthermore, a frenzy around the...

  Tim Oldham – CEO & Managing Director – AdAlta (ASX:1AD) is a clinical-stage biotechnology company using its i-body platform to discover and develop next-generation protein therapeutics addressing drug targets that are challenging for...

ASX health sector rises in line with broader markets in the past five days  AdAlta reports positive Phase 1 extension trial results of AD-214 into IPF Mach7 signs $3.1 million, three-year renewal contract with Penn State Health Morgans h...

AdAlta (ASX:1AD) has announced results from its Phase 1 extension study of lead asset AD-214 in development for fibrotic diseases, including the debilitating and fatal disease Idiopathic Pulmonary Fibrosis.

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Local markets end slightly higher IT Sector slumps 1.2pc Small Caps led by AT1   The ASX 200 traded sideways again today, closing the day +0.1% higher as gains in Financials and Real Estate were offset by losses in Tech and Mining stocks....

Phase I extension study of AD-214 tested the target Phase II dose of AD-214 in healthy volunteers AdAlta says the findings positively answer key partner questions and support progressing AD-214 Phase II clinical studies in Idiopathic Pulmo...

Top-line results from a Phase I extension study of AdAlta’s (ASX: 1AD) lead asset AD-214 in the treatment of fibrotic disease have established the safety, tolerability and bioavailability of a target dose for planned Phase II clinical studi...

06 Mar 2024 - A snapshot of the stocks on the move, featuring Atomo Diagnostics (ASX:AT1), AdAlta (ASX:1AD) and Aruma Resources (ASX:AAJ).

  To register for Friday's webinar click here. Atomo Diagnostics (ASX:AT1) has announced securing purchase orders from Viatris Healthcare Pty Ltd for approximately AUD $970,000 worth of HIV Self-Tests, manufactured by Atomo under the Mylan...

Atomo jumps 90pc after reporting a significant sales order AdAlta up 20pc after revealing key results from Phase 1 study Race Oncology’s drug shows potent anticancer activity    Atomo up 90pc on HIV kit sales Atomo Diagnostics (ASX:AT1)...

Stockhead’s Top 10 at 11, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percenta...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  ASX200 dragged down by bad drugs The IT Sector is up 1.1pc, Healthcare is down about 3.2pc Small cap winners led by American Rare Earths and Appen   The benchmark was shot through the heart by CSL this morning leaving everything else in...